ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary

ADC Therapeutics SA

09/05/2023 13:52

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 74 cents​​ per share for the quarter ended in March. The mean
expectation of seven analysts for the quarter was for a loss
of 67 cents per share.
    * Revenue fell 59.2% to $18.99 million from a year ago;
analysts
expected $20.09 million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 74 cents​.
    * The mean earnings estimate of analysts had fallen by
about 213.1% in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * ADC Therapeutics SA shares had risen by 8.7% this
quarter and
lost 44.8% so far this year.
    * The company reported a quarterly loss of $59.43 million.
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 12:52 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.67          -0.74          Missed
 Dec. 31 2022      -0.29          -0.30          Missed
 Sep. 30 2022      -0.35          -0.65          Missed
 Jun. 30 2022      -0.91          -0.84          Beat